In this multicentre, open-label, randomised controlled trial, adults with T1D and HbA1c ≥58 mmol/mol, already using CGM/isCGM with insulin therapy (multiple daily injections or pump), were enrolled across eight sites in Sweden and Norway. The gene discussed is INS; the disease is type 1 diabetes mellitus.